Idiopathic pulmonary arterial hypertension: Current state of play and new treatment modalities

J. Simon R Gibbs, Craig Broberg, Michael A. Gatzoulis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Research in pulmonary hypertension has led to exciting advances over the last decade, both in terms of understanding aetiology and expanding treatment options. This review highlights the current approach to classification and disease management. In particular, we review the significant data and recommendations on the use of prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors and drug combinations.

Original languageEnglish (US)
Pages (from-to)7-10
Number of pages4
JournalInternational Journal of Cardiology
Volume97
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Phosphodiesterase Inhibitors
Epoprostenol
Drug Combinations
Disease Management
Pulmonary Hypertension
Research
Endothelin Receptor Antagonists
Familial Primary Pulmonary Hypertension

Keywords

  • Phosphodiesterase
  • Prostacyclin
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Idiopathic pulmonary arterial hypertension : Current state of play and new treatment modalities. / Gibbs, J. Simon R; Broberg, Craig; Gatzoulis, Michael A.

In: International Journal of Cardiology, Vol. 97, No. SUPPL. 1, 12.2004, p. 7-10.

Research output: Contribution to journalArticle

@article{c9649b02dc944d82adaf328098233ddb,
title = "Idiopathic pulmonary arterial hypertension: Current state of play and new treatment modalities",
abstract = "Research in pulmonary hypertension has led to exciting advances over the last decade, both in terms of understanding aetiology and expanding treatment options. This review highlights the current approach to classification and disease management. In particular, we review the significant data and recommendations on the use of prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors and drug combinations.",
keywords = "Phosphodiesterase, Prostacyclin, Pulmonary hypertension",
author = "Gibbs, {J. Simon R} and Craig Broberg and Gatzoulis, {Michael A.}",
year = "2004",
month = "12",
doi = "10.1016/j.ijcard.2004.08.003",
language = "English (US)",
volume = "97",
pages = "7--10",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Idiopathic pulmonary arterial hypertension

T2 - Current state of play and new treatment modalities

AU - Gibbs, J. Simon R

AU - Broberg, Craig

AU - Gatzoulis, Michael A.

PY - 2004/12

Y1 - 2004/12

N2 - Research in pulmonary hypertension has led to exciting advances over the last decade, both in terms of understanding aetiology and expanding treatment options. This review highlights the current approach to classification and disease management. In particular, we review the significant data and recommendations on the use of prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors and drug combinations.

AB - Research in pulmonary hypertension has led to exciting advances over the last decade, both in terms of understanding aetiology and expanding treatment options. This review highlights the current approach to classification and disease management. In particular, we review the significant data and recommendations on the use of prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors and drug combinations.

KW - Phosphodiesterase

KW - Prostacyclin

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=10044223335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044223335&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2004.08.003

DO - 10.1016/j.ijcard.2004.08.003

M3 - Article

C2 - 15590073

AN - SCOPUS:10044223335

VL - 97

SP - 7

EP - 10

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - SUPPL. 1

ER -